Daily News

Daily News

Silymarin decreases severity of acute pancreatitis in experimental research

South Korea Daily Report

2020 JAN 13 (NewsRx) -- By a News Reporter-Staff News Editor at South Korea Daily Report -- Researchers detail new data in Digestive System Diseases and Conditions - Acute Pancreatitis. According to news reporting originating in Jeonbuk, South Korea, by NewsRx journalists, research stated, “In this study, we investigated the anti-inflammatory effects of silymarin on cerulein-induced acute pancreatitis (AP) in mice. Cerulein (50 mu g/kg) was injected intraperitoneally once hourly for 6 hours to induce AP.”

Financial support for this research came from National Research Foundation of Korea (NRF) - Korean government (MEST).

The news reporters obtained a quote from the research from Wonkwang University, “To investigate the prophylactic effects of silymarin, dimethyl sulfoxide or silymarin (25, 50, and 100 mg/kg) was injected intraperitoneally 1 hour before cerulein injection. To investigate the therapeutic effects of silymarin, dimethyl sulfoxide or silymarin (100 mg/kg) was injected intraperitoneally 1, 3, or 5 hours after the first cerulein injection. Blood, pancreas, and lungs were harvested 6 hours after the last cerulein injection. Pre- and posttreatment with silymarin decreased the pancreas weight/body weight ratio and serum amylase activity. Furthermore, silymarin treatment inhibited pancreas and lung injury and neutrophil infiltration during cerulein-induced AP. In addition, silymarin inhibited increased secretion of proinflammatory cytokines such as interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha. Finally, mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B were activated by cerulein, and only p38 in MAPK was inhibited by silymarin.”

According to the news reporters, the research concluded: “These findings suggest that silymarin attenuates the severity of AP through inhibition of p38 MAPKs and that silymarin could be a potential prophylactic and therapeutic agent for the treatment of AP.”

For more information on this research see: Silymarin Attenuates the Severity of Cerulein-induced Acute Pancreatitis. Pancreas, 2020;49(1):89-95. Pancreas can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Pancreas - http://journals.lww.com/pancreasjournal/pages/default.aspx)

Our news correspondents report that additional information may be obtained by contacting S.J. Park, Wonkwang University, Dept. of Herbology, School of Korean Medicine, Iksan Daero 460, Iksan 54538, Jeonbuk, South Korea. Additional authors for this research include M.J. Kim, D.U. Kim, J.W. Choi, H.J. Song, D.G. Kim and G.S. Bae.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/MPA.0000000000001453. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)